Healthcare Industry News: LifeCell
News Release - July 14, 2008
Tornier Reaches the 100,000 Implant Milestone with the Aequalis Shoulder SystemEDINA, Minn.--(HSMN NewsFeed)--Tornier Inc., a global leader in extremity orthopedics headquartered in Edina, MN, today announced that orthopedic physicians around the world have now implanted more than 100,000 Aequalis Shoulders. The Tornier Aequalis Shoulder was introduced in Europe in 1994 and is a complete shoulder arthroplasty system indicated for use in patients with severe osteo-arthritis or those in need of shoulder replacement surgery as a result of severe trauma. The Aequalis Shoulder provides physicians an anatomically correct shoulder option which many published studies have shown can reduce pain and restore mobility.
Doug Kohrs, President and CEO of Tornier, commented, “Tornier and all of its employees are very proud that more than 100,000 patients around the world have experienced significant quality of life improvements as a result of treatment with an Aequalis shoulder. Over the years, Tornier has sought out strong physician product development input, and it is through those close collaborations that enduring products like the Aequalis Shoulder are able to reach the market. Tornier remains committed to further improving patient outcomes through this collaborative effort with key industry thought leaders specializing in shoulder repair.”
Dr. Thomas Norris of California Pacific Medical Center in San Francisco, commented, “Providing an anatomically correct shoulder was a significant step forward in improving patient outcomes. The Aequalis® Shoulder Series provides our patients with an option that may allow them to be pain free and regain nearly full mobility in the post surgical period.”
Dr. Gilles Walch, of Centre Santy, in Lyon, France and one of the original designers of the Aequalis Shoulder, said, “With the Aequalis Shoulder, Tornier has pioneered technology that provides the physician the opportunity to adapt the implant to the individual patient anatomy. The outcomes reported in numerous studies worldwide, supported with up to ten year follow up data, clearly demonstrates that surgical results with the Aequalis Shoulder are reproducible and long lasting, thereby demonstrating the safety and efficacy of this gold standard technology.”
Mr. Kohrs added, “The Aequalis Shoulder Series has made a significant contribution to the expansion of the role of shoulder arthroplasty in orthopedic surgery today. We are committed to further enhancements of the Aequalis product line, and we look forward to the opportunity to supply our customers with the next 100,000 implants within the next five years.”
An Overview of the Aequalis ® Shoulder Series by Tornier
- The Cemented Total Shoulder: a non-constrained prosthesis designed to reproduce the anatomy of the gleno-humeral joint
- The Press-Fit Total Shoulder: unique surface geometry and macro-structure promote maximum bone support and on-growth for long-term fixation
- The Aequalis-Glenoid System: designed to give intra-operative flexibility between the implantation of a keeled or pegged glenoid
- The Fracture Shoulder System: hemi-arthroplasty for three and four-part fractures of the proximal humerus
- The “Reversed” Shoulder System: switches the traditional ball and socket design to address the rotator cuff deficient patient.
- Resurfacing Head: allows for the restoration of normal joint mechanics and stability of the shoulder with minimal bone resection
Tornier develops and markets orthopedic medical devices designed to restore function and return patients to an active and healthy lifestyle. The company's innovative extremity products include the Aequalis® line of shoulder arthroplasty prostheses, the Salto™ and Salto Talaris™ total ankle prostheses, and a broad portfolio of foot and hand products including the NexFix™ system for reconstructive foot surgery and CoverLoc™ system for wrist fracture repair. Tornier has also established collaborations with innovative materials companies such as BioSurface Engineering Technologies, LifeCell, Bioretec, and Tepha in order to access novel non-metal technologies that may better address unmet soft and hard tissue repair needs of orthopedic surgeons and their patients. For more information regarding Tornier, visit www.tornier-us.com.
For more information regarding Tornier, visit www.tornier-us.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.